Trial Profile
Multiple Dose Safety and Preliminary Pharmacodynamic Study of PPI-1019 in Subjects With Mild-Moderate Alzheimer's Disease
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 24 Aug 2020
Price :
$35
*
At a glance
- Drugs PPI 1019 (Primary)
- Indications Alzheimer's disease
- Focus Adverse reactions
- Sponsors Praecis Pharmaceuticals
- 27 Sep 2006 Status change
- 22 Oct 2005 New trial record.